Gaurav Syal

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 6

Top Topics

Ulcerative Colitis

Randomized Controlled Trial

Patient Reported

Disease Activity

Top Venues

Digestive diseases and sciences

Inflammatory bowel diseases

This page only lists publications with an associated author ORCID identifier.

Publications

Gaurav Syal, Daniel S Mishkin, Andrea Banty, Susie Lee, Norma Fontelera, Melissa Hampton, David Ziring, Phillip R Fleshner, Gil Y Melmed
Effectiveness of Oral Tofacitinib in Chronic Pouchitis: A Prospective, Open-Label Pilot Study. Inflammatory bowel diseases (2023)
Gaurav Syal, Gil Y Melmed, Christopher V Almario, Brennan M R Spiegel
Azathioprine Withdrawal Is Cost-Effective in Patients with Crohn's Disease in Remission on Infliximab and Azathioprine. Digestive diseases and sciences 68 (2) (2022)
Gaurav Syal, Gil Y Melmed, Christopher V Almario, Brennan M R Spiegel
Azathioprine Withdrawal Is Cost-Effective in Patients with Crohn's Disease in Remission on Infliximab and Azathioprine. Digestive diseases and sciences 68 (2) (2022)
Gaurav Syal, Gil Y Melmed, Christopher V Almario, Brennan M R Spiegel
Azathioprine Withdrawal Is Cost-Effective in Patients with Crohn's Disease in Remission on Infliximab and Azathioprine. Digestive diseases and sciences 68 (2) (2022)
Gaurav Syal, Miles P Sparrow, Fernando Velayos, Adam S Cheifetz, Shane Devlin, Peter M Irving, Gilaad G Kaplan, Laura E Raffals, Thomas Ullman, Krisztina B Gecse, Phillip R Fleshner, Amy L Lightner, Corey A Siegel, Gil Y Melmed
Appropriateness of Medical and Surgical Treatments for Chronic Pouchitis Using RAND/UCLA Appropriateness Methodology. Digestive diseases and sciences 67 (10) (2022)
Gaurav Syal, Gil Y Melmed, Christopher V Almario, Brennan M R Spiegel
Azathioprine Withdrawal Is Cost-Effective in Patients with Crohn's Disease in Remission on Infliximab and Azathioprine. Digestive diseases and sciences (2022)